Form 4: Sangamo Therapeutics CEO Reports Routine Share Disposition for Tax Withholding

Sangamo Therapeutics' President and CEO, Sandy Macrae, reported the disposition of 126,950 shares of common stock for mandatory tax withholding purposes related to the vesting of restricted stock units.

Summary

• Sandy Macrae, President, CEO, and Director of Sangamo Therapeutics, Inc. (SGMO), reported a transaction involving company common stock.
• On July 22, 2025, 126,950 shares were disposed of at a price of $0.4798 per share.
• This disposition was solely for mandatory tax withholding purposes related to the vesting of restricted stock units (RSUs) and was not a discretionary trade by the Reporting Person.
• Following this transaction, Macrae beneficially owns 2,191,460 shares of Sangamo Therapeutics common stock.
• The remaining beneficial ownership includes shares from RSU grants from January 22, 2024, February 24, 2023, and February 25, 2025, with various future vesting schedules through January 2026 and February 2026, subject to continuous service.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction for tax withholding related to RSU vesting, which is neutral in sentiment. It does not indicate positive or negative company performance or strategic shifts.

Future Outlook

The filing does not provide a future outlook for the company's business or financial performance. It only details future vesting schedules for existing RSU grants.

Industry Context

This Form 4 filing is a routine insider transaction report common across all publicly traded companies. It does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or gene therapy sector where Sangamo Therapeutics operates.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, non-discretionary transaction for tax purposes. It reflects the ongoing equity compensation structure for executives.

Next Steps

• Remaining portions of the January 22, 2024 RSU grant will vest in successive equal quarterly installments through January 22, 2026.
• Remaining portions of the February 24, 2023 RSU grant will vest in successive equal quarterly installments through February 24, 2026.
• The February 25, 2025 RSU grant will vest as to one-fourth (1/4) of the shares on February 25, 2026, with the remainder vesting in 8 successive equal quarterly installments thereafter.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Tax Withholding, Beneficial Ownership, Sandy Macrae, CEO, Director